glp 1 receptor agonists and dpp 4 inhibitors GLP-1 agonist versus DPP-4 inhibitor kidney and cardiovascular outcomes in clinical practice in type-2 diabetes do not combine dpp-4 inhibitors

The lipid-modifying effects should be considered as part of a broader cardiometabolic benefit profile rather than a primary indication for cholesterol management

Gastroenterology 2015;149:330339

Hirsch EC, Hunot S

The winner may be the company that best balances efficacy, tolerability, supply, pricing, payer coverage, and patient persistence

With these advancements, there is still a significant possibility to produce innovative treatments that increase the efficacy, safety, quality, and durability of weight reduction

Research shows that GLP-1 effectively reduces neuroinflammation by decreasing pro-inflammatory cytokine release and inhibiting microglia activation